The Daavlin Company introduced a new high intensity, targeted phototherapy device at the February 2008 meeting of the American Academy of Dermatology in San Antonio, Texas. Granted 510K clearance from the FDA for the treatment of psoriasis, vitiligo and atopic dermatitis, the device will be marketed under the tradename Lumera.
A patented feature of this new device is a fiber optic brush that delivers UV directly to the scalp through an array of bristles in a footprint that measures 2 x 10 cm. For treatment of other areas of the body, there is an interchangeable spotlight that can deliver energy in a variety of beam shapes. The spectral output of the device is in the UVB waverange.
Targeted phototherapy is a method for treating lesional skin tissue without affecting non-involved skin areas. Also, in those diseases where the lesional skin is thicker or more resistant to ultraviolet penetration, targeted phototherapy allows the practitioner to treat at higher dose levels because the erythemal threshold of the non-involved skin does not have to be considered.
Click HERE to learn more about the Lumera.
To contact your sales representative, click HERE to visit our territory map.